10.22
전일 마감가:
$9.83
열려 있는:
$9.965
하루 거래량:
92,195
Relative Volume:
0.10
시가총액:
$485.83M
수익:
$89.04M
순이익/손실:
$-241.08M
주가수익비율:
-1.943
EPS:
-5.26
순현금흐름:
$-194.72M
1주 성능:
+11.47%
1개월 성능:
+44.68%
6개월 성능:
+16.04%
1년 성능:
-38.70%
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
RGNX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RGNX
Regenxbio Inc
|
10.21 | 485.83M | 89.04M | -241.08M | -194.72M | -5.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
501.38 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
605.48 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
652.82 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
260.13 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
258.31 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
2025-02-07 | 재개 | Raymond James | Outperform |
2024-11-15 | 재개 | Morgan Stanley | Overweight |
2024-10-10 | 재개 | Raymond James | Outperform |
2024-06-07 | 개시 | Goldman | Buy |
2024-03-11 | 개시 | H.C. Wainwright | Buy |
2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2024-02-21 | 재개 | Raymond James | Outperform |
2023-11-01 | 개시 | Stifel | Buy |
2023-06-02 | 개시 | Robert W. Baird | Outperform |
2022-06-23 | 개시 | Berenberg | Buy |
2021-12-15 | 개시 | Wedbush | Neutral |
2021-10-19 | 재개 | Morgan Stanley | Overweight |
2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2020-12-16 | 개시 | UBS | Buy |
2020-06-25 | 재개 | BofA/Merrill | Buy |
2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
2019-06-14 | 재개 | Raymond James | Outperform |
2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
2018-11-08 | 재확인 | BofA/Merrill | Neutral |
2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
2018-05-09 | 재확인 | Barclays | Overweight |
2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2018-02-13 | 개시 | Mizuho | Neutral |
2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights - Citizen Tribune
REGENXBIO Inc. (NASDAQ:RGNX) Shares Fly 34% But Investors Aren't Buying For Growth - simplywall.st
BlackRock, Inc. Reduces Stake in Regenxbio Inc: A Strategic Port - GuruFocus
REGENXBIO to Host Conference Call on May 12 to Discuss First Qua - GuruFocus
REGENXBIO Q1 2025 Earnings Call: Financial Results and Key Operations Update Coming May 12 - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Regenxbio Inc’s Market Journey: Closing Weak at 5.93, Down -5.72 - DWinneX
Is REGENXBIO (NASDAQ:RGNX) A Risky Investment? - simplywall.st
REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Geode Capital Management LLC - Defense World
Form 8-KCurrent report - ADVFN
Regenxbio (RGNX) Gains Following Positive FDA Comments on Gene Therapies - GuruFocus
Vanguard Group Inc. Trims Stake in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
RGNX stock touches 52-week low at $5.6 amid sharp annual decline - Investing.com Nigeria
RGNX stock touches 52-week low at $5.6 amid sharp annual decline By Investing.com - Investing.com South Africa
When (RGNX) Moves Investors should Listen - news.stocktradersdaily.com
Clear Street sets Regenxbio stock Buy rating, $50 target By Investing.com - Investing.com Australia
Clear Street sets Regenxbio stock Buy rating, $50 target - Investing.com India
5 Reasons To Buy Regenxbio Right Now (NASDAQ:RGNX) - Seeking Alpha
REGENXBIO partners with Nippon Shinyaku for MPS therapies - MSN
Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing - insights.citeline.com
RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating - TipRanks
REGENXBIO’s DMD Gene Therapy RGX-202 Generates Microdystrophin Expression in Additional Patients Treated in Phase 1/2 Trial - CGTLive™
Regenxbio Rises After Duchenne Update And Sarepta Safety Scare - insights.citeline.com
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Regenxbio’s RGX-202 continues to show promise in DMD - The Pharma Letter
Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old - Clinical Trials Arena
Regenxbio stock target raised to $29 at Raymond James By Investing.com - Investing.com Canada
REGENXBIO reports promising gene therapy trial results By Investing.com - Investing.com South Africa
Baird maintains Regenxbio stock outperform rating, $39 target By Investing.com - Investing.com South Africa
Baird maintains Regenxbio stock outperform rating, $39 target - Investing.com
Regenxbio stock target raised to $29 at Raymond James - Investing.com India
Regenxbio up 4% following additional data on Duchenne gene therapy asset - MSN
Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial - Benzinga
Regenxbio Says New Data Support Potential Gene Therapy for Duchenne Muscular Dystrophy - MarketScreener
REGENXBIO reports promising gene therapy trial results - Investing.com India
REGENXBIO: New Interim Data Reinforces Potential Of RGX-202Quick Facts - Nasdaq
Breakthrough: REGENXBIO DMD Gene Therapy Achieves Unprecedented 122% Protein Expression - StockTitan
Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha
Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements - Investing.com
Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements By Investing.com - Investing.com Canada
H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy By Investing.com - Investing.com Philippines
REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner - Yahoo Finance
H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy - Investing.com India
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):